COHANCE.NS Stock Surges 37% in April 2026 on NSE

Cohance Lifesciences Limited (COHANCE.NS) delivered a powerful rally in after-hours trading on April 28, 2026, with COHANCE.NS stock surging 37% to ₹493.30 on the NSE. The pharmaceutical company, which rebranded from Suven Pharmaceuticals following its merger effective May 1, 2025, is capturing investor attention as a contract development and manufacturing (CDMO) specialist. Trading volume exploded to 40.86 million shares, nearly 6 times the average daily volume. The Hyderabad-based firm specializes in active pharmaceutical ingredients (APIs) and specialty chemicals. This momentum reflects growing confidence in the company’s transformation and market positioning within India’s healthcare sector.

COHANCE.NS Stock Performance and Price Action

COHANCE.NS stock has delivered exceptional returns across multiple timeframes. The stock opened at ₹444.45 and climbed to a day high of ₹514.90, showcasing strong intraday momentum. Over the past month, COHANCE.NS stock gained 42.75%, while the one-day jump of 19.99% reflects today’s after-hours strength.

Technical Strength Signals Overbought Conditions

Technical indicators reveal aggressive buying pressure. The Relative Strength Index (RSI) stands at 73.89, signaling overbought territory. The MACD histogram at 6.41 with a signal line of 13.85 confirms positive momentum. The Average True Range (ATR) of 22.41 shows elevated volatility. However, the Average Directional Index (ADX) at 36.42 indicates a strong underlying trend. Money Flow Index (MFI) at 90.24 suggests institutional accumulation despite overbought readings.

Valuation Metrics and Financial Health

COHANCE.NS stock trades at a PE ratio of 85.06, reflecting premium valuation relative to earnings. The price-to-sales ratio stands at 8.06, indicating investors are pricing in significant future growth. Market capitalization reached ₹1.65 trillion, making it a mid-cap pharmaceutical player. The company maintains a healthy balance sheet with a debt-to-equity ratio of just 0.12 and current ratio of 2.92.

Growth Drivers and Profitability

Revenue grew 13.91% year-over-year, while gross profit expanded 20.91%. The net profit margin of 9.83% demonstrates operational efficiency. Return on equity (ROE) of 8.63% and return on assets (ROA) of 3.62% show moderate capital efficiency. Free cash flow per share reached ₹6.68, providing financial flexibility. The company’s EPS of ₹5.08 reflects solid earnings generation despite the high PE multiple.

Market Sentiment and Trading Activity

After-hours trading in COHANCE.NS stock revealed exceptional liquidity and institutional interest. Volume surged to 40.86 million shares, representing a relative volume of 5.91 times normal levels. This spike indicates strong conviction among market participants about the company’s prospects.

Liquidation and Momentum Indicators

The On-Balance Volume (OBV) reached 65.87 million, confirming sustained buying pressure throughout the session. The Awesome Oscillator at 52.09 and Rate of Change at 43.22% demonstrate powerful upside momentum. Williams %R at 0.00 suggests maximum buying strength. Stochastic indicators (%K at 73.98, %D at 65.58) confirm overbought momentum. Track COHANCE.NS on Meyka for real-time updates on volume patterns and sentiment shifts.

Meyka AI Grade and Price Forecast

Meyka AI rates COHANCE.NS stock with a grade of B, suggesting a HOLD recommendation with a total score of 67.50. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The grading system weighs sector comparison at 16%, industry comparison at 16%, financial growth at 12%, and key metrics at 16%.

Forward Outlook and Forecast Model

Meyka AI’s forecast model projects COHANCE.NS stock reaching ₹1,020.84 within 12 months, implying 107% upside from current levels. The three-year forecast stands at ₹1,250.12, while the five-year projection reaches ₹1,480.15. These forecasts are model-based projections and not guarantees. The yearly forecast suggests significant appreciation potential, though investors should note the current overbought technical conditions. Earnings announcement is scheduled for May 28, 2026, which could provide fresh catalysts or corrections.

Final Thoughts

COHANCE.NS stock delivered a remarkable 37% surge on April 28, 2026, reflecting strong market confidence in Cohance Lifesciences’ transformation and CDMO positioning. The explosive volume and overbought technical indicators suggest aggressive institutional accumulation, though valuations at 85x PE warrant caution. The company’s solid revenue growth of 13.91%, healthy balance sheet, and Meyka AI’s B-grade rating provide fundamental support. However, the RSI at 73.89 and MFI at 90.24 signal potential near-term consolidation. Investors should monitor the May 28 earnings announcement closely, as it will provide critical guidance on profitability trends and capital allocation. The five-year fo…

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.